Information Provided By:
Fly News Breaks for December 3, 2019
Dec 3, 2019 | 07:30 EDT
Needham analyst Matt McGinley initiated coverage of Curaleaf Holdings with a Buy rating and $7.25 price target. The analyst expects the coming year to see the company transition from a period of acquisition and developmental investment to integration and operational growth, optimizing its dispensary assets in medical and adult-use legal markets across 19 states. McGinley further believes that Curaleaf can triple its revenue in 2020 while boosting its EBITDA from "modestly positive" to at least $225M.
News For CURLF From the Last 2 Days
There are no results for your query CURLF